Chimeric antigen receptor modified T-cells for cancer treatment

T cells engineered with the chimeric antigen receptor (CAR) are rapidly emerging as an important immunotherapy for hematologic malignancies. The anti-cluster of differentiation (CD)19 CAR-T cell therapy has been remarkably successful against refractory/relapsed acute lymphoblastic leukemia (ALL), an...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Xiao, Wang, Yao, Han, Wei-Dong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Chinese Medical Association 2018
Materias:
Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6309024/
https://www.ncbi.nlm.nih.gov/pubmed/30603741
http://dx.doi.org/10.1016/j.cdtm.2018.08.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6309024/
https://www.ncbi.nlm.nih.gov/pubmed/30603741
http://dx.doi.org/10.1016/j.cdtm.2018.08.002

Ejemplares similares